Tirzepatide Side Effects: What Studies Report

Evidence tier: Established. Tirzepatide is a prescription dual GIP and GLP-1 receptor co-agonist that has been studied in large, randomised, controlled phase 3 programmes in type 2 diabetes and in obesity, with published safety tables and, more recently, a dedicated cardiovascular outcomes trial. This page summarises what those published papers reported about adverse events. It does not describe how any product is used, and it is not a substitute for a prescribing clinician's judgement. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, symptom, or treatment question.

What the Published Trials Measured

Safety data on tirzepatide come mainly from the SURPASS programme in type 2 diabetes and the SURMOUNT programme in obesity, plus systematic reviews pooling those datasets. In the 72-week obesity trial, researchers randomised 2,539 adults to once-weekly tirzepatide 5 mg, 10 mg, or 15 mg or placebo and reported mean weight changes of −15.0%, −19.5%, and −20.9% versus −3.1% with placebo (PMID 35658024). A narrative review of the dual GIP/GLP-1 mechanism described the same compound's effects on glycaemic control and body weight across the diabetes programme (PMID 36050763). A phase 1 mechanistic trial examined pancreatic islet function and insulin sensitivity in adults with type 2 diabetes against placebo or semaglutide (PMID 35468322).

Adverse-event reporting in these papers followed standard trial conventions: investigators tabulated treatment-emergent events by dose group, graded severity, and counted discontinuations. That structure matters when interpreting side-effect questions, because the published figures describe groups of trial participants under protocol supervision, not individuals.

When Do Tirzepatide Side Effects Start: What Studies Report

The obesity trial publication stated that gastrointestinal adverse events occurred primarily during the dose-escalation period rather than after participants reached and remained on a maintenance dose (PMID 35658024). In other words, the clustering that researchers described in that report was tied to periods when the weekly amount was being increased under the trial protocol. A pooled systematic review and meta-analysis of once-weekly tirzepatide for weight management, updated to include SURMOUNT-2, similarly reported that gastrointestinal events were the dominant adverse-event category separating tirzepatide from placebo (PMID 38850440).

None of the verified papers provide a day-by-day onset curve for an individual. What they do report is a pattern: early and escalation-linked gastrointestinal complaints, with severity most often classified as mild to moderate (PMID 35658024).

How Long Do Tirzepatide Side Effects Last: What Studies Report

Duration is reported indirectly. Trial authors characterised gastrointestinal events as transient and largely confined to escalation rather than persisting through maintenance dosing across the 72-week treatment period (PMID 35658024). The three-year extension of that obesity programme followed participants to 176 weeks and reported mean weight changes of −12.3%, −18.4%, and −19.7% with tirzepatide 5 mg, 10 mg, and 15 mg versus −1.3% with placebo, with a safety profile the investigators described as consistent with earlier reports rather than showing new or escalating toxicity over time (PMID 39536238).

The comparative trial against once-weekly semaglutide 1 mg over 40 weeks in type 2 diabetes reported nausea, diarrhoea and vomiting as the most common adverse events in both arms, with gastrointestinal events generally dose-related for tirzepatide (PMID 34170647). Persistence beyond a trial's observation window is not something these publications can answer.

Gastrointestinal Adverse Events: What Studies Report

Across the verified literature, the same four events recur: nausea, diarrhoea, vomiting, and constipation. The monotherapy phase 3 trial in type 2 diabetes reported that the most frequent adverse events with tirzepatide were mild-to-moderate gastrointestinal events across the 40-week treatment period (PMID 34186022). The pooled weight-management meta-analysis reported that these events were more frequent with tirzepatide than with placebo while overall serious adverse events were not markedly different between groups (PMID 38850440).

Discontinuation for Adverse Events: What Studies Report

Discontinuation counts are one of the more interpretable safety figures because they capture events that participants and investigators judged intolerable. In the 72-week obesity trial, researchers reported that adverse events led to treatment discontinuation in 4.3%, 7.1%, and 6.2% of participants receiving tirzepatide 5 mg, 10 mg, and 15 mg, compared with 2.6% receiving placebo (PMID 35658024). The pooled meta-analysis of weight-management trials likewise examined withdrawal due to adverse events alongside efficacy outcomes (PMID 38850440).

Pancreatitis, Gallbladder and Biliary Events: What Studies Report

A 2023 systematic review and meta-analysis was designed specifically around these signals, pooling type 2 diabetes and obesity trials to examine pancreatitis and gallbladder or biliary disease with tirzepatide (PMID 37908750). The authors reported that event numbers were low and that the pooled analyses did not demonstrate a statistically significant increase in overall risk versus comparators, while noting that the small number of events limited precision (PMID 37908750). Reviews of this kind are hypothesis-testing rather than definitive; the authors' own caveat about event counts is part of the finding.

Hypoglycaemia and Metabolic Signals: What Studies Report

In the head-to-head trial against semaglutide in type 2 diabetes, researchers reported that hypoglycaemia was infrequent in all treatment groups over 40 weeks (PMID 34170647). The phase 1 mechanistic study measured pancreatic islet function and insulin sensitivity rather than clinical endpoints, comparing subcutaneous tirzepatide with placebo or semaglutide in adults with type 2 diabetes (PMID 35468322). A 2025 summary of cardiometabolic parameters in obesity collated reported changes across blood pressure, lipids and related measures for tirzepatide (PMID 40555920).

Cardiovascular Outcomes: What Studies Report

A dedicated cardiovascular outcomes trial compared tirzepatide with dulaglutide in participants who had type 2 diabetes and atherosclerotic cardiovascular disease; the design and baseline characteristics paper set out the major adverse cardiovascular event endpoint and the enrolled population (PMID 37758044). The results publication reported that tirzepatide was non-inferior to dulaglutide for major adverse cardiovascular events in that population (PMID 41406444). Separately, a 2025 JAMA analysis examined semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction, a group in which tolerability and volume status are of particular clinical interest (PMID 40886075).

Is Tirzepatide Contraindicated With Any Medications?

Contraindications and interaction warnings are set by the approved product labelling in each jurisdiction and by the prescribing clinician — not by the trial literature summarised here. What the verified papers do describe is how trials handled concomitant therapy: the monotherapy trial in type 2 diabetes studied tirzepatide without background glucose-lowering drugs (PMID 34186022), while the comparative trial studied it against semaglutide in participants on metformin (PMID 34170647). The cardiovascular outcomes programme enrolled participants with established atherosclerotic disease who were typically receiving multiple cardiovascular medications, as described in its baseline characteristics paper (PMID 37758044).

None of these publications is an interaction study. Questions about combining tirzepatide with insulin, sulfonylureas, oral contraceptives, anticoagulants, or any other medication belong with a prescriber and pharmacist who can check the current label and an individual medication list.

Smoking, Vaping and Nicotine: What the Literature Covers

The verified trial and review literature on tirzepatide does not contain an analysis of smoking, vaping, or nicotine exposure during treatment. The obesity and diabetes trials recorded adverse events and baseline characteristics but did not publish smoking-stratified tolerability or nicotine interaction analyses in the reports cited here (PMID 35658024, PMID 34170647). This is a genuine evidence gap rather than a reassuring finding: absence of published analysis is not evidence of absence of effect. Because both nicotine and gastrointestinal adverse events can independently affect nausea and appetite, clinicians are the appropriate source for individual questions, and cardiovascular risk considerations discussed in the outcomes literature apply to the underlying population regardless (PMID 41406444).

5-Amino-1MQ Alongside Tirzepatide: What the Literature Covers

5-amino-1MQ is an investigational small molecule studied preclinically as a nicotinamide N-methyltransferase inhibitor. It is not an approved medicine, and no trial or review in the verified tirzepatide literature summarised on this page evaluated it in combination with tirzepatide. The published tirzepatide safety datasets — including the 72-week obesity trial and its 176-week extension — describe tirzepatide given alone or with defined background therapy, not with unapproved investigational agents (PMID 35658024, PMID 39536238). Where no combination data exist, the honest summary is simply that the question has not been studied in humans.

How to Read These Numbers

• Group averages, not predictions. Percentages such as the discontinuation figures reported in the obesity trial describe cohorts, not individuals (PMID 35658024).
• Comparator matters. Adverse-event rates versus placebo differ from rates versus an active GLP-1 receptor agonist (PMID 34170647).
• Rare events need pooling. Signals such as pancreatitis and biliary disease were addressed by meta-analysis precisely because single trials had too few events (PMID 37908750).
• Trial populations are selected. Enrolment criteria in the cardiovascular outcomes programme shaped which comorbidities were represented (PMID 37758044).

Where This Page Fits

This page is limited to safety and adverse-event reporting. For the pharmacology of dual GIP/GLP-1 receptor agonism, the structure of the SURPASS and SURMOUNT programmes, and how trial endpoints were defined, PeptideU's tirzepatide course covers that material in teaching format without duplicating the adverse-event summaries above.

Trademark and Independence Notice

Tirzepatide is the international nonproprietary name of an active pharmaceutical ingredient. Branded products containing tirzepatide are marketed under trade names owned by their manufacturer; any such name is a trademark of its owner and is used here only for identification. PeptideU is an independent educational publisher, sells nothing, and is not affiliated with or endorsed by any manufacturer, marketer, distributor, or regulatory body. Prescribing information, contraindications and warnings are defined by the approved labelling in each jurisdiction and by licensed clinicians.

References

• Tirzepatide Once Weekly for the Treatment of Obesity (The New England Journal of Medicine, 2022)
• Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction (Cardiovascular Diabetology, 2022)
• Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis (Frontiers in Endocrinology, 2023)
• Tirzepatide for Obesity Treatment and Diabetes Prevention (The New England Journal of Medicine, 2025)
• Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence (Diabetes, Obesity & Metabolism, 2025)
• Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial (Endocrine, 2024)
• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (The New England Journal of Medicine, 2021)
• Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (JAMA, 2025)
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)
• Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a phase 1 clinical trial (The Lancet Diabetes & Endocrinology, 2022)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (The New England Journal of Medicine, 2025)